资讯

Merck is in a tight spot, balancing blockbuster Keytruda’s looming 2028 patent cliff and rough seas in China’s market.
Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...
A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...
Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 ...
Merck offers a 4.2% dividend yield but faces uncertainty with KEYTRUDA's LOE. Click here to find out why MRK stock is a Hold.
Merck is expanding in oncology, immunology, and vaccines through acquisitions and R&D. Find out what makes MRK a stable GARP ...
Merck stock lags industry as Keytruda dependency, Gardasil woes in China, and tariff risks cloud outlook despite pipeline ...
After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...
Petosemtamab is projected to reach $1.2bn in global sales by 2030, while ficerafusp alfa will reach $620 million.
US drugmaker Merck &Co will present data on the use of its PD-1 inhibitor Keytruda in four new cancer types later this week as it jostles for territory in the fast-growing immuno-oncology sector.
This downturn can be attributed to several factors: a lowered guidance for 2025 and growing concerns about the long-term ...
Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...